BioPharmSignal logoBioPharmSignal

Biotech News

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Disc Medicine (IRON)Disc MedicineEarnings

Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) to be shared at the American Society of Clinical Oncology (ASCO) Annual

Open original release

Related news

IRONDisc Medicine2026-02-26 13:30 EST

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

GERNGeron2026-05-06 11:00 EST

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

SNDXSyndax Pharmaceuticals2026-04-30 20:01 EST

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

RIGLRigel Pharmaceuticals2026-04-28 12:05 EST

Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results

SNDXSyndax Pharmaceuticals2026-04-24 11:00 EST

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

ZNTLZentalis2025-11-10 21:05 EST

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

GERNGeron2026-02-25 12:00 EST

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

View all latest news

Disc Medicine

Disc Medicine is a hematology company focused on iron disorders and related blood-disease biology. Its story is built around developing therapies for conditions where iron regulation is central.

Recent company news

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

IRONDisc Medicine2026-06-01 12:30 EST

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

IRONDisc Medicine2026-05-12 13:30 EST

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

IRONDisc Medicine2026-05-05 12:30 EST

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-04-21 14:00 EST

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Stock data

Close
74.61 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States